We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
- Authors
Joseph, Nisha S.; Kaufman, Jonathan L.; Gupta, Vilas A.; Hofmeister, Craig C.; Dhodapkar, Madhav V.; Boise, Lawrence H.; DiCamillo, Sara M.; Roberts, Danielle; Nooka, Ajay K.; Lonial, Sagar
- Abstract
Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd backbone in terms of improved both depth of response and long-term survival benefit as measured by progression-free survival (PFS). Our group has previously published on a historical cohort of 1000 NDMM patients uniformly treated with RVd induction with impressive both PFS and overall survival. Here, we present a comparative analysis of our RVd cohort with a recent cohort of 326 patients induced with Dara-RVd at our institution with intent to transplant. This analysis demonstrates the utility of this regimen in real-world clinical practice and provides additional insights into D-RVd performance in patient subsets often underrepresented in clinical trials, as well as the impact of daratumumab in maintenance for NDMM patients.
- Subjects
SEQUENTIAL analysis; OVERALL survival; MULTIPLE myeloma; PROGRESSION-free survival; LENALIDOMIDE
- Publication
Blood Cancer Journal, 2024, Vol 14, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-024-01120-9